Callan Capital LLC Has $6.74 Million Position in Neumora Therapeutics, Inc. (NASDAQ:NMRA)

Callan Capital LLC decreased its holdings in shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) by 3.8% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 636,194 shares of the company’s stock after selling 25,000 shares during the quarter. Callan Capital LLC owned approximately 0.39% of Neumora Therapeutics worth $6,744,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in NMRA. Windmill Hill Asset Management Ltd lifted its position in Neumora Therapeutics by 299.6% during the fourth quarter. Windmill Hill Asset Management Ltd now owns 104,373 shares of the company’s stock worth $1,106,000 after acquiring an additional 78,252 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Neumora Therapeutics during the 4th quarter worth approximately $61,000. SkyOak Wealth LLC lifted its holdings in Neumora Therapeutics by 33.3% during the 4th quarter. SkyOak Wealth LLC now owns 20,000 shares of the company’s stock worth $212,000 after purchasing an additional 5,000 shares during the last quarter. China Universal Asset Management Co. Ltd. bought a new stake in Neumora Therapeutics in the 4th quarter valued at $363,000. Finally, JPMorgan Chase & Co. grew its holdings in Neumora Therapeutics by 2.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 64,421 shares of the company’s stock valued at $851,000 after buying an additional 1,629 shares in the last quarter. 47.65% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on NMRA. Needham & Company LLC reissued a “buy” rating and set a $23.00 target price on shares of Neumora Therapeutics in a report on Thursday, January 2nd. JPMorgan Chase & Co. cut shares of Neumora Therapeutics from an “overweight” rating to a “neutral” rating and dropped their price objective for the stock from $18.00 to $15.00 in a research note on Tuesday, November 5th. Royal Bank of Canada downgraded shares of Neumora Therapeutics from an “outperform” rating to a “sector perform” rating and cut their price objective for the company from $29.00 to $4.00 in a report on Thursday, January 2nd. Bank of America lowered their target price on shares of Neumora Therapeutics from $22.00 to $7.00 and set a “buy” rating on the stock in a report on Monday, January 6th. Finally, HC Wainwright reiterated a “buy” rating and issued a $30.00 price target on shares of Neumora Therapeutics in a research note on Friday, February 14th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $16.50.

Neumora Therapeutics Price Performance

NMRA stock opened at $1.80 on Friday. The company’s 50-day moving average price is $4.30 and its two-hundred day moving average price is $9.33. Neumora Therapeutics, Inc. has a 12 month low of $1.60 and a 12 month high of $21.00.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.